Drug intelligence / Profile preview

ProLNG-S

Development stage: Preclinical
Modality: Small Molecules

Overview

ProLNG-S is a cholesterol-conjugated derivative of resiquimod (R848), designed to function as a Toll-like receptor 7/8 (TLR7/8) agonist. It aims to enhance immune efficacy and reduce toxicity, particularly in the context of cancer vaccines. When formulated as ProLNG-001, a positively charged liposome, ProLNG-S effectively targets secondary lymphoid organs, leading to a robust systemic anti-tumor immune response and tumor-specific T cell activation. This mechanism is intended to prevent tumor progression and improve survival by stimulating both innate and adaptive immune responses through T cells.

Targets

TLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on ProLNG-S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProLNG-S.

Explore the full profile